PL2121605T3 - Sposób otrzymywania (1R,2S,5S)-N-[(1S)-3-amino-1-(cyklobutylo-metylo)-2,3-dioksypropylo]-3-[(2S)-2-[[[(1,1-dimetyloetylo)amino]-karbonylo]amino]-3,3-dimetylo-1-oksybutylo]-6,6-dimetylo-3-azabicyklo[3.1.0]heksano-2-karboksyamidu - Google Patents

Sposób otrzymywania (1R,2S,5S)-N-[(1S)-3-amino-1-(cyklobutylo-metylo)-2,3-dioksypropylo]-3-[(2S)-2-[[[(1,1-dimetyloetylo)amino]-karbonylo]amino]-3,3-dimetylo-1-oksybutylo]-6,6-dimetylo-3-azabicyklo[3.1.0]heksano-2-karboksyamidu

Info

Publication number
PL2121605T3
PL2121605T3 PL07867798T PL07867798T PL2121605T3 PL 2121605 T3 PL2121605 T3 PL 2121605T3 PL 07867798 T PL07867798 T PL 07867798T PL 07867798 T PL07867798 T PL 07867798T PL 2121605 T3 PL2121605 T3 PL 2121605T3
Authority
PL
Poland
Prior art keywords
amino
dimethyl
dioxopropyl
oxobutyl
cyclobutylmethyl
Prior art date
Application number
PL07867798T
Other languages
English (en)
Inventor
George S K Wong
Hong-Chang Lee
Jennifer A Vance
Weidong Tong
Tetsuo Iwama
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PL2121605T3 publication Critical patent/PL2121605T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL07867798T 2006-12-20 2007-12-18 Sposób otrzymywania (1R,2S,5S)-N-[(1S)-3-amino-1-(cyklobutylo-metylo)-2,3-dioksypropylo]-3-[(2S)-2-[[[(1,1-dimetyloetylo)amino]-karbonylo]amino]-3,3-dimetylo-1-oksybutylo]-6,6-dimetylo-3-azabicyklo[3.1.0]heksano-2-karboksyamidu PL2121605T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87644706P 2006-12-20 2006-12-20
EP07867798.6A EP2121605B1 (en) 2006-12-20 2007-12-18 Process for preparing (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
PCT/US2007/025804 WO2008079216A1 (en) 2006-12-20 2007-12-18 Process for preparing (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

Publications (1)

Publication Number Publication Date
PL2121605T3 true PL2121605T3 (pl) 2014-05-30

Family

ID=39232899

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07867798T PL2121605T3 (pl) 2006-12-20 2007-12-18 Sposób otrzymywania (1R,2S,5S)-N-[(1S)-3-amino-1-(cyklobutylo-metylo)-2,3-dioksypropylo]-3-[(2S)-2-[[[(1,1-dimetyloetylo)amino]-karbonylo]amino]-3,3-dimetylo-1-oksybutylo]-6,6-dimetylo-3-azabicyklo[3.1.0]heksano-2-karboksyamidu

Country Status (13)

Country Link
US (1) US8163937B2 (pl)
EP (1) EP2121605B1 (pl)
JP (1) JP4955779B2 (pl)
CN (1) CN101611000B (pl)
AR (1) AR064465A1 (pl)
CA (1) CA2672620A1 (pl)
ES (1) ES2439246T3 (pl)
HR (1) HRP20131156T1 (pl)
MX (1) MX2009006884A (pl)
PL (1) PL2121605T3 (pl)
PT (1) PT2121605E (pl)
WO (1) WO2008079216A1 (pl)
ZA (1) ZA200904330B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
AU2012250799A1 (en) * 2011-05-04 2013-10-10 Merck Sharp & Dohme Corp. Processes for preparing inhibitors of the hepatitis C virus
CN103508918B (zh) * 2012-06-18 2015-09-09 上海医药工业研究院 带有环丁基的α-羟基β-氨基酯类化合物及其制备方法
WO2014061034A1 (en) * 2012-10-18 2014-04-24 Msn Laboratories Limited Process for preparation of boceprevir and intermediates thereof
WO2014083575A2 (en) 2012-11-29 2014-06-05 Mylan Laboratories Ltd Improved process for the preparation of boceprevir intermediate
CN103936818B (zh) * 2013-01-18 2017-09-29 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅰ及其制备方法和应用
CN103936651B (zh) * 2013-01-18 2016-06-22 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅲ及其制备方法和应用
CN103936652B (zh) * 2013-01-18 2016-07-06 上海医药工业研究院 抗丙肝药物Boceprevir的中间体IV及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000627A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
AR049635A1 (es) * 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c

Also Published As

Publication number Publication date
US20100145013A1 (en) 2010-06-10
CA2672620A1 (en) 2008-07-03
WO2008079216A1 (en) 2008-07-03
US8163937B2 (en) 2012-04-24
MX2009006884A (es) 2009-07-03
AR064465A1 (es) 2009-04-01
HK1133261A1 (en) 2010-03-19
PT2121605E (pt) 2014-02-11
JP2010513499A (ja) 2010-04-30
CN101611000B (zh) 2013-08-21
ZA200904330B (en) 2010-04-28
ES2439246T3 (es) 2014-01-22
CN101611000A (zh) 2009-12-23
EP2121605B1 (en) 2013-11-20
HRP20131156T1 (hr) 2014-01-03
EP2121605A1 (en) 2009-11-25
JP4955779B2 (ja) 2012-06-20

Similar Documents

Publication Publication Date Title
PT2121605E (pt) Processo para preparar (1r,2s,5s)-n-[(1s)-3-amino-1- (ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2-[[[(1,1- dimetiletil)amino]-carbonil]amino]-3,3-dimetil-1-oxobutil]- 6,6-dimetil-3-azabiciclo[3.1.0]hexano-2-carboxamida
ZA200509100B (en) Process and intermediates for the preparation of (1r,2s,5s)-3-azabicyclo[3,1,0,]hexane-2-carboxamide,n-[3-amino-1-(cyclobutylmethyl)-2,3-doixopropyl]-3-[(2s)-2-[[[1,1-dimethylethyyl]amino]carbonylamino]-3,3-dimethyl-1-oxobuthyl]-6,6-dimethyl
USD585754S1 (en) Fragrance bottle and cap
EP2455460A3 (en) Lipase variants for pharmaceutical use
WO2010100477A3 (en) Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
USD641255S1 (en) Combined funnel and bottle
CA2796215C (en) Compositions and methods for brain delivery of analgesic peptides
EP2368871B8 (en) Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol
IL182581A (en) Processes for the preparation of a polypeptide containing l-tyrosine, l-alanine, l-glutamate and l-lysine
GEP20125385B (en) Antibodies directed against amyloid-beta peptide and methods using same
EP2112907A4 (en) PEARL FOR SEWING, VACUUM CAP FOR SUCKING AN INNER ORGAN AND DEVICE FOR SEWING AN INNER ORGAN
WO2012087051A3 (en) Microparticles containing physiologically active peptide, method for preparing the same, and pharmaceutical composition comprising the same
JP2012506408A5 (pl)
PH12014502405A1 (en) Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carb on yl}-2,2-dimethylpropyl]carbamate
EP2301569A3 (en) Vaccine and method for treatment of neurodegenerative diseases
ZA200804110B (en) An oxidation process for the preparation of N-[3-amino-1-(cyclobutylmethyl)-2,3- dioxopropyl]-3-{N-[(tert-buty-lamino)carbonyl]-3-methyl-L-valyl}-6,6-dimethyl-3-azabicy-clo[3.1.0]hexane-2-carboxamide and related compounds
SI2921168T1 (sl) Sestavek n-(((7s)-3,4-dimetoksibiciklo(4.2.0)okta-1,3,5-trien-7-il)metil)-3-( 7,8-dimetoksi-1,2,4,5-tetrahidro-3h-3-benzazepin-3-il)-n-metil-3-okso-1- propanamina in perindoprila
WO2008082486A3 (en) Preparation of 3-amino-3-(cyclobutylmethyl)-2-(hydroxy)-propionamide hydrochloride
WO2008076316A3 (en) Bisulfite purification of an alpha-keto amide
WO2008055059A8 (en) Bi-functional peptides for multiple sclerosis treatment and diagnosis
WO2008071755A3 (fr) Peptides derives de la caseine ayant une activité anxiolytique
MX2007005988A (es) Procedimiento sintetico para compuestos de eter aminociclohexilico.
WO2010057275A8 (en) Cyclic peptides and uses thereof
PT2952521T (pt) Péptidos derivados da proteína plpb humana, polinucleótidos que codificam os referidos péptidos e anticorpos dirigidos contra os referidos péptidos
WO2009017775A3 (en) Process for the preparation of a polypeptide